Stay updated with breaking news from அர்ஜுன் பாலார். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
email article Adding a targeted agent to chemotherapy failed to improve survival as initial therapy for metastatic urothelial carcinoma, a randomized trial showed. Median overall survival (OS) was about 14 months with cisplatin-containing chemotherapy when paired with either placebo or the angiogenesis inhibitor bevacizumab (Avastin). Progression-free survival (PFS), a secondary endpoint, favored the bevacizumab arm (8.0 vs 6.7 months). Grade ≥3 adverse events (AEs) occurred in a similar proportion of patients in each arm, although bevacizumab-related toxicities occurred more often with the addition of the angiogenesis inhibitor, reported Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center in New York City, and colleagues, in the ....